DepoMed, Inc. (NASDAQ: DEPO) reported Q4 EPS of $0.72, which may not compare with the analyst estimate of ($0.21). Revenue ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE